Ofatumumab As Initial Therapy For Indolent B Cell Lymphomas: A Phase II Trial

被引：1
|
作者：
Barnes, Jeffrey A.
Feng, Yang
Hochberg, Ephraim P.
Takvorian, Tak
Weitzman, James
Fisher, David C.
Jacobsen, Eric D.
Joyce, Robin
Neuberg, Donna S.
Abramson, Jeremy S.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.3062.3062
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3062
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [1] Increased Dose Rituximab Followed by Maintenance Rituximab As Initial Therapy for Indolent B Cell Lymphomas: A Phase II Trial
    Barnes, Jeffrey A.
    Stevenson, Kristen
    Hochberg, Ephraim P.
    Takvorian, Tak
    Fisher, David C.
    LaCasce, Ann
    Brown, Jennifer R.
    Mahindra, Anuj K.
    Neuberg, Donna
    Abramson, Jeremy S.
    BLOOD, 2011, 118 (21) : 1587 - 1588
  • [2] A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B-cell lymphomas
    Vannata, Barbara
    Vanazzi, Anna
    Negri, Mara
    Liptrott, Sarah Jayne
    Bartosek, Anna Amalia
    Miani, Monica
    Di Sanzo, Alessandro
    Cavalli, Franco
    Zucca, Emanuele
    Stathis, Anastasios
    HEMATOLOGICAL ONCOLOGY, 2021, 39 (01) : 60 - 65
  • [3] Indolent B cell lymphomas
    Campo, E.
    VIRCHOWS ARCHIV, 2010, 457 (02) : 113 - 113
  • [4] DEFERRAL OF INITIAL THERAPY FOR ADVANCED INDOLENT LYMPHOMAS
    PORTLOCK, CS
    CANCER TREATMENT REPORTS, 1982, 66 (03): : 417 - 419
  • [5] Bortezomib plus modified R-CHOP as initial therapy for indolent B-cell lymphomas: Phase I results
    Flowers, C.
    Sinha, R.
    Kaufman, J.
    Shenoy, P.
    Lewis, C.
    Bumpers, K.
    Rogatko, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Phase II Trial of Lenalidomide - Rituximab ± Dexamethasone in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab
    Ahmadi, Tahamtan
    Chong, Elise A.
    Gordon, Amanda
    Aqui, Nicole A.
    Xu, YinYan
    Svoboda, Jakub
    Nasta, Sunita D.
    Schuster, Stephen J.
    BLOOD, 2011, 118 (21) : 122 - 123
  • [7] Phase II Trial of Lenalidomide - Dexamethasone - Rituximab In Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab
    Ahmadi, Tahamtan
    Chong, Elise A.
    Gordon, Amanda
    Leinbach, Leah
    Aqui, Nicole A.
    Nasta, Sunita D.
    Svoboda, Jakub
    Goldstein, Steven C.
    Schuster, Stephen J.
    BLOOD, 2010, 116 (21) : 1616 - 1616
  • [8] Phase II Trial of Lenalidomide - Dexamethasone - Rituximab in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab.
    Ahmadi, Tahamtan
    Chong, Elise A.
    Gordon, Amanda
    Aqui, Nicole A.
    Downs, Lisa H.
    Leinbach, Leah
    Goldstein, Steven C.
    Nasta, Sunita D.
    Janofsky, Stephen
    Maniar, Tapan N.
    Svoboda, Jakub
    Schuster, Stephen J.
    BLOOD, 2009, 114 (22) : 677 - 677
  • [9] Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin’s lymphoma
    Myron S. Czuczman
    Stephen Kahanic
    Andres Forero
    Glen Davis
    Mihaela Munteanu
    Eric Van Den Neste
    Fritz Offner
    Dominique Bron
    Donald Quick
    Nathan Fowler
    Annals of Hematology, 2015, 94 : 633 - 641
  • [10] Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma
    Czuczman, Myron S.
    Kahanic, Stephen
    Forero, Andres
    Davis, Glen
    Munteanu, Mihaela
    Van den Neste, Eric
    Offner, Fritz
    Bron, Dominique
    Quick, Donald
    Fowler, Nathan
    ANNALS OF HEMATOLOGY, 2015, 94 (04) : 633 - 641
12345